Soon after last month’s end of her turbulent two-year run as CEO of X (formerly Twitter), Linda Yaccarino has landed another ...

New research reveals that obesity-related cancer deaths in the U.S. have surged within 20 years, with obesity linked to 13 ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Linda Yaccarino, the former CEO of the Elon Musk-owned social media platform X, has a new leadership gig in the weight loss space.

Dr. Tim Church predicted recently that GLP-1 agonists, GLP-1 /GIP agonists and similar prescription drugs will soon be as ...

The eMed Population Health digital health platform announced Tuesday that former X Chief Executive Officer Linda Yaccarino ...

The company has launched the ad campaign with three patient ambassadors: Brian, Jeanette and Jennifer, each of whom is ...

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

Danish pharmaceutical giant Novo Nordisk A/S (NVO) is facing serious headwinds. After enjoying a strong run fueled by demand ...

Hims & Hers Health, Inc. HIMS delivered an earnings per share (EPS) of 17 cents in second-quarter 2025 compared with the year ...

Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by Eli Lilly as just one ...

Hims & Hers Health (HIMS) stock falls after reporting lower Q2 revenues. Analysts caution about near-term challenges, ...